櫻井 政寿

Medicine & Life Sciences

1. Hematopoietic Stem Cell Transplantation 100%
2. Human Herpesvirus 6 36%
3. Leukemia, Myelogenous, Chronic, BCR-ABL Positive 24%
4. Graft vs Host Disease 16%
5. Protein-Tyrosine Kinases 16%
6. Transplantation 16%
7. Myelitis 14%
8. Hematopoietic Stem Cells 14%
9. Tacrolimus 12%
10. Fetal Blood 12%
11. Lymphoma 12%
12. Calcineurin Inhibitors 11%
13. Melphalan 11%
14. Myelodysplastic Syndromes 11%
15. Toxoplasmosis 11%
16. Leukemia, Myeloid, Chronic Phase 10%
17. Lymphoma, Large B-Cell, Diffuse 10%
18. Japan 10%
19. Cytomegalovirus 10%
20. Stem Cell Transplantation 10%
21. Acute Myeloid Leukemia 9%
22. Encephalitis 9%
23. Stem Cells 9%
24. Human Herpesvirus 6 encephalitis 9%
25. Voriconazole 9%
26. AIC246 9%
27. Bacterial Pneumonia 8%
28. Ondansetron 8%
29. Transplants 8%
30. Hematologic Neoplasms 8%
31. Allogeneic Cells 8%
32. Immunoglobulins 8%
33. Lung 8%
34. Vomiting 8%
35. bosutinib 8%
36. fludarabine 8%
37. ponatinib 7%
38. Steroids 7%
39. 4-methyl-N-(3-(4-methylimidazol-1-yl)-5-(trifluoromethyl)phenyl)-3-((4-pyridin-3-ylpyrimidin-2-yl)amino)benzamide 7%
40. Polyomavirus Infections 7%
41. B-Lymphocytes 7%
42. Dasatinib 7%
43. Gallium-67 7%
44. Trichosporon 7%
45. Aprepitant 7%
46. Pure Red-Cell Aplasia 7%
47. plerixafor octahydrochloride 6%
48. Cytomegalovirus Retinitis 6%
49. Fungemia 6%
50. T-Lymphocytes 6%